HK/China Healthcare Analyst (ex-Fosun Pharma)

Xinyao (Criss) Wang

Over 15 years' experience in both finance and healthcare, covering clinic operations, investment and equity research in both China and overseas.

China Healthcare Weekly (Sep.24) - VBP on Neuro-Intervention, Payment System Changes, AI in Drug R&D

Aier Eye Hospital Group (300015.CH) - The Concerns Behind the High Growth Momentum

Pre-IPO Sirnaomics Ltd. - Cautious Optimism Is Still Recommended

WuXi Biologics (2269 HK) - The Strength and the Potential Risk

Pre-IPO Novotech Holdings - The Future Would Not Be Easy

WuXi AppTec (2359.HK) - The Certainties and the Uncertainties

Battle Lines Drawn As BABA Builds Out First/Last-Mile Capacity; But Who Will Fund 75+ Bn CNY CapEx?

Equity Bottom-Up

<p>On August 12, 2021, <a href="https://www.smartkarma.com/entities/wuxi-apptec-co-ltd-bf4a1265-beef-48b6-b82d-29308426030f" target="_blank" data-smartkarma-citation="entities:27795:1" rel="noopener">WuXi AppTec Co. Ltd. (2359 HK)</a> released its 2021 interim results. Revenue grew 45.7% YoY to RMB10,537 million in 2021/1H. Driven by the robust revenue growth, the net profit attributable to owners of the Company increased 55.8% YoY to RMB2,675 million, accounting for about 90% of the net profit in the whole year of 2020. It can be seen that WuXi AppTec’s performance maintained outstanding growth momentum. This insight mainly analyzed the 2021/1H performance, the business model, the concerns and the outlook of the Company.</p>

On August 12, 2021, WuXi AppTec Co. Ltd. (2359 HK) released its 2021 interim results. Revenue grew 45.7% YoY to RMB10,537 million in 2021/1H. Driven by the robust revenue growth, the net profit attributable to owners of the Company increased 55.8% YoY to RMB2,675 million, accounting for about 90% of the net profit in the whole year of 2020. It can be seen that WuXi AppTec’s performance maintained outstanding growth momentum. This insight mainly analyzed the 2021/1H performance, the business model, the concerns and the outlook of the Company.

Asymchem Laboratories Tianjin (002821 CH)

WuXi AppTec (603259.CH/2359.HK) - The Smart Business Model